{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-013169","form_type":"8-K","ticker":"ALT","cik":"0001326190","company_name":"Altimmune, Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.386491+00:00","generated_at":"2026-06-24T00:41:30.176549+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Altimmune Q2 net loss $20.1M ($0.42/share); cash $184.8M; pemvidutide Phase 1b data mid-Sept","bullets":["Net loss of $20.1M ($0.42 per share) for Q2 2022 vs $24.8M ($0.60) in Q2 2021, which included $8.1M impairment.","Cash, equivalents, and short-term investments $184.8M at June 30, 2022.","R&D expenses $16.0M in Q2 2022, up from $13.3M, primarily on pemvidutide development.","Pemvidutide Phase 1b obesity/NAFLD topline data expected mid-September 2022; Phase 2 MOMENTUM interim analysis (160 subjects) expected Q1 2023.","HepTcell Phase 2 chronic hepatitis B trial enrollment ongoing; data expected H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-013169","json":"https://secwatch.observer/filing/0001558370-22-013169.json","markdown":"https://secwatch.observer/filing/0001558370-22-013169.md","text":"https://secwatch.observer/filing/0001558370-22-013169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326190/000155837022013169/0001558370-22-013169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326190/000155837022013169/alt-20220811x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:41:30.176549+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}